Background {#Sec1}
==========

Estimates of cancer prevalence are widely based on limited duration prevalence, including only patients living after a cancer diagnosis made in the previous 5 years \[[@CR1], [@CR2]\]. Prevalence, regardless of the time since diagnosis (i.e., complete prevalence), is less frequently estimated than limited duration prevalence \[[@CR3]--[@CR9]\]. Overall age-standardized cancer incidence and mortality rates have declined over the past 10 years in the majority of high income countries, whereas the complete prevalence has been consistently increasing in the early 2000s \[[@CR3], [@CR4], [@CR6], [@CR8], [@CR10], [@CR11]\]. Complete prevalence is generally measured in absolute numbers and proportions, i.e., not age-standardized. Thus, improved survival \[[@CR12], [@CR13]\] and population ageing (increasing absolute number of new cancer diagnoses) imply a progressive increase in tumour prevalence.

Cancer prevalence includes patients currently treated for cancer; those who have become cancer free, but still have a measurable excess risk of recurrence or death; and, finally, patients having death rates similar to those of the general population who can be considered "cured patients" \[[@CR14]\]. Many of these individuals are possibly affected by physical, cognitive, and/or psychosocial limitations \[[@CR15]\].

The aim of this study was to provide a description of the number of people living in Italy at January 1, 2010 after a cancer diagnosis, for all cancers combined and for a selection of cancer types by sex, age, and time since diagnosis. In addition, projections of cancer prevalence in Italy are presented up to the year 2020. Estimates and projections of complete tumour prevalence and characteristics of prevalent patients are necessary to help clinicians and health care planners in improving long-term care of patients and in allocating appropriately health care resources. Moreover, they may provide helpful information to a growing number of cancer patients or former patients.

Methods {#Sec2}
=======

Study design and data sources {#Sec3}
-----------------------------

This is a descriptive analysis of individual data collected during the period 1976-2009 from 27 population-based Italian cancer registries (i.e., 32% of the entire Italian population in 2010), which agreed to participate in the study and were able to provide at least 7 years of cancer registration as of December 31, 2009 ([Appendix 1](#Sec10){ref-type="sec"}) and follow-up of vital status as of December 31, 2013. The Italian legislation identifies Cancer Registries as collectors of personal data for surveillance purposes without explicit individual consent. The approval of a research ethic committee is not required, since this descriptive study was conducted without any direct or indirect intervention on patients.

Prevalence for all malignant tumours (ICD-10: C00-C43, C45-C96) and 34 cancer types or their combinations were estimated and presented in this study for all age groups. Urinary bladder cancers with benign or uncertain behaviour, and in situ tumours were also included. Only non melanoma skin cancers (ICD-10 C44) were excluded. ICD-O-3 morphology codes were used to define specific subtypes.

Statistical methods {#Sec4}
-------------------

The clinical and demographic characteristics of the persons registered with a diagnosis of cancers in the Italian CRs were used to estimate: 1) how many of them were still alive at January 1, 2010 regardless of time since diagnosis -i.e., complete prevalence count- by cancer type, sex, and age group; 2) the prevalence proportion in Italy at 2010 for each cancer type, by sex, and age; 3) the complete prevalence (count and proportion) at 1st January 2015 and 2020, overall and by time since diagnosis; and 4) describe the changing over time of these estimates.

For each cancer registry we computed the limited duration prevalence, i.e. the number of patients diagnosed in the period of the registration activity (between 7 and 34 years) at January 1, 2010, using the counting method implemented in SEER\*Stat software \[[@CR16]\]. This maximum limited duration prevalence was corrected, using the COMPREV software \[[@CR17]\], by means of completeness index \[[@CR18], [@CR19]\], to estimate the total number of cancer patients alive, regardless of when they were diagnosed. Completeness indices were estimated by cancer type, sex, age, and time since diagnosis. Prevalence was computed as an absolute number, as well as a proportion per 100,000 residents people by cancer type, sex, age group, area of residence, and years since diagnosis. Patients with more than one primary cancer were included in the computation of prevalence for each cancer type or combination. In the analyses for all types combined, only the first cancer was considered. Completeness indices were obtained by statistical regression models of incidence and survival using data from 8 long-term registries ([Appendix 1](#Sec10){ref-type="sec"}) with an available observation period of at least 18 years before 2010 \[[@CR20], [@CR21]\]. Relative survival and incidence functions were estimated by means of parametric models within the period 1985-2011 for survival and 1985-2009 for incidence. The survival model was a parametric cure model assuming that a proportion of individuals with cancer were bound to die (fatal cases) with a survival following a Weibull distribution, while the remaining proportion (cured fraction) had the same mortality rate as that of the general population with the same age and gender stratification \[[@CR14], [@CR20]\]. The parameters of the survival model were estimated by cancer type, sex, and age class (0-14, 15-44, 45-54, 55-64, 65-74, 75+ years) through the SAS procedure NLIN. A period effect was included on the hazard of dying of cancer. Incidence data were categorised according to cancer type, sex, five-year age group, and birth cohort (\< 1899, 1900-1904,..., 2005-2009). A sixth degree polynomial age-cohort model of crude incidence rates was fitted through the SAS LOGISTIC procedure for each cancer type and sex \[[@CR21]\].

Complete prevalence proportions were projected to 2020 by cancer type, sex, age, and registry, assuming that complete prevalence will follow a linear function, based on the trend of the last three calendar years (i.e., 2007-2009). This simplified assumption (linear and constant trend) may not be valid for long-term projections, but it is reasonable for short or medium-term (e.g., 10-year) ones. Other assumptions (e.g., log-linear models) were explored \[[@CR4], [@CR6]\], showing consistent results for common cancer types, but unstable projections for the rarest.

The absolute number of prevalent cases in Italy was obtained using proportions of prevalence estimates (age-, sex-, and cancer type-specific) from CRs included in this study, multiplied by the Italian national population by sex and age observed at January 1, 2010. Proportions projected to 2020 were thus multiplied to Italian population forecasted at January 1, 2020 \[[@CR22]\].

Results {#Sec5}
=======

Prevalence estimates at 2010 {#Sec6}
----------------------------

In Italy in 2010, 2,637,975 persons were alive after a cancer diagnosis, corresponding to 4.6% of all the Italian population ([Appendix 2](#Sec11){ref-type="sec"}). Prevalence proportions increase with age: 3.1% at age 45-54 years, 6.6% at 55-64 years, 12.1% at 65-74 years, and nearly 17% after age 75 years ([Appendix 2](#Sec11){ref-type="sec"}) with differences by sex (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Complete cancer prevalence by cancer type and age in Italian men at January 1, 2010Cancer typePrevalent casesPrevalence proportion per 100,000 menAll ages%00-1415-4445-5455-6465-7475-8485+All ages00-1415-4445-5455-6465-7475-8485+All types but skin non-melanoma1,194,033484484,17287,091198,505363,932357,05198,43942501117322079571513,02920,53421,955Upper aero-digestive tract26,7452.2%1916543320653680635786136710001584199311337313Esophagus30670.3%05425272211057811531201723455140Stomach45,9703.8%27642583666113,61816,538580215806581804709261268Small intestine33840.3%02213507609878502161302823385246Colon, rectum, anus185,53215.5%32718872229,33259,93163,69821,130654023210840210836184682Liver17,4541.5%573171539383163474752610632337110228280142Biliary tract42510.4%0702387131365144342115006204780103Pancreas58560.5%319859813831876146233621021439698475Larynx44,8103.8%02362105839915,08214,81941691600251240540854965Lung63,0485.3%16804277111,01422,76521,682399621907643067871229890Thymus, heart, mediastinum22900.2%423844355485163313371391418189Bone48080.4%152191092477159641837163162021192210Skin melanoma44,9773.8%2167307411981711,11778672014165061181291408470488Mesothelioma20900.2%07212745791346654801313342712Kaposi sarcoma56110.5%356765886412551498766210517264690174Connective tissue11,7571.0%2262685169620432459200264741623415987111144Penis42850.4%091413795130912554221401922456884Prostate305,04425.5%3438338734,764112,958122,37631,118111205881048413871436878Testis37,9373.2%8617,116849553493317238911871332149197152128133243Kidney62,8155.3%3142842560912,65219,61317,52442622267251343647031030984Bladder192,61116.1%252802858228,94859,20470,74922,302686026204821210440745053Choroidal melanoma18010.2%0115209365484519109701611183025Brain and central nervous system16,1101.3%568539128812930252514233915413466581827866Thyroid25,5122.1%31642858115876466523513498915613716516613680Hodgkin lymphoma27,8212.3%165968554885229413326844379548312913914114899Non-Hodgkin lymphoma56,8084.8%6298344875411,69113,80211,18524032031472206339501655574Leukemias36,1053.0%1939762040865656805067032051124436594158276373444Multiple myeloma (plasma cell)12,7871.1%0326115826364050368093845032775143215207Table 2Complete cancer prevalence by cancer type and age in Italian women at January 1, 2010Cancer typePrevalent casesPrevalence proportion per 100,000 womenAll ages%00-1415-4445-5455-6465-7475-8485+All ages00-1415-4445-5455-6465-7475-8485+All types but skin non-melanoma1,443,9423903112,527176,656277,374363,646357,146152,6904836939884095749611,24313,99414,500Upper aero-digestive tract15,4331.1%19156216873156369636241688540144187123148158Esophagus11250.1%01710219934835810140036131611Stomach35,5372.5%065118963992861912,95374261170541104254497698Small intestine25970.2%0136277495688752250901614212928Colon, rectum, anus171,84711.9%122754864024,51745,32259,47931,123571024204658137722872901Liver73310.5%612583719432182292658925129256811458Biliary tract55650.4%360286836151719329311800622447284Pancreas62710.4%032649512391699173378021031133556869Larynx44070.3%268364898121113585081601826415552Lung23,7211.6%561123734933715866621980800653133224268186Thymus, heart, mediastinum22120.2%61514406410443306727249912117Bone91240.6%1002259216319501306973374283194347383832Skin melanoma57,5154.0%3010,718992910,95011,65799534278198198237302372404432Mesothelioma6740.0%018681482241744220024885Kaposi sarcoma19900.1%01056019734975052870126123049Connective tissue99170.7%20318931399181218901791929345173249627191Breast604,84141.9%026,66382,068128,514165,456142,65859,4832046023619063516516456435751Vagina and vulva96890.7%172565579822377357019313202132771137183Cervix uteri58,8794.1%44321807310,56913,17715,6417093193038184280397591675Corpus uteri (endometrium)103,3217.2%01490574521,04731,54831,15812,33334201313555396411981147Ovary45,6203.2%654058661710,54411,39997293209149134154276352372291Kidney35,2502.4%411236928415290946110,650422912292168149293436418Bladder47,8223.3%613622562610111,41016,786959416401262172359676897Choroidal melanoma17130.1%014921029444541420260149141821Brain and central nervous system23,1451.6%5016210366135653875397813557212528296114133105Thyroid93,3416.5%6822,81321,80521,59716,956857815243072199498571521356153Hodgkin lymphoma20,4331.4%10291163990310422221401498672799384675843Non-Hodgkin lymphoma53,9073.7%2625635662610,91713,61512,7314120181649153290422505407Leukemias31,1962.2%1450744534654400562660672742101346478115166235256Multiple myeloma (plasma cell)12,2780.9%0217887236736113814138241022264112150124

Men living in Italy after a cancer diagnosis in 2010 were 1,194,033, corresponding to 4.3% (4250/100,000) of all Italian male population (Table [1](#Tab1){ref-type="table"}). This proportion increased from less than 1% below the age of 45 years, to \> 20% for men aged ≥75 years. The most frequent tumours in terms of prevalence were prostate (305,044 of prevalent cases at January, 1st 2010) representing 25.5% of all cases or 1.1% of all Italian men, followed by bladder (192,611 men, 16.1%) and colorectal (185,532 men, 15.5%) tumours.

Italian women living after a cancer diagnosis were 1,443,942 (Table [2](#Tab2){ref-type="table"}), corresponding to 4.8% of all Italian women. Breast cancer represented 41.9% of all cancers (604,841), followed by colorectal cancers (171,847, 11.9% of all female prevalent cases, 0.6% of all Italian women) and by endometrial cancers (103,321, 7.2% and 0.3%, respectively). Notably, the fourth most frequent cancer type diagnosed in Italian prevalent women is thyroid (93,341 women, 6.5% of all female prevalent cases). Prevalent women were younger than men. Women aged 15-44 years living after a diagnosis represented 1% of the whole Italian population, they were 4% at ages 45-54 years, 7% at ages 55-64 years, 11% at ages 65-74 years, and 14% for women aged ≥75 years (Table [2](#Tab2){ref-type="table"}).

More than 1.5 million people (i.e., 2.7% of all Italian residents) were alive after ≥5 years since diagnosis. They were 60% of all prevalent cases, 64% of women and 55% of men. The distribution of prevalent cases by time since diagnosis depends on cancer type (Fig. [1](#Fig1){ref-type="fig"}). The percentage of prevalent cases diagnosed since less than 2 years varied from 39% for lung cancer patients to 15% for female breast and 7% for cervical cancer patients. Conversely, the percentage of prevalent cases diagnosed ≥15 years before was 59% for cervical cancer, 35% for stomach cancer and 31% for endometrial cancer, but only 4% for prostate and 13% for lung cancer patients. Notably, patients diagnosed ≥15 years before were 21% of all prevalent cases (16% among men and 25% among women).Fig. 1Complete prevalence by time since diagnosis for selected cancer types\* in Italy at January 1, 2010. \*Cancer types diagnosed in \> 50,000 persons, sorted by number of cases

Prevalence projections for 2020 {#Sec7}
-------------------------------

In 2020, there will be 3.6 million prevalent cancer cases in Italy (Table [3](#Tab3){ref-type="table"}), 1.9 million women and 1.7 million men, with a 10-year increase of 37% (41 and 33% in men and women, respectively). In 2020, 2.6% of all Italian women (0.8 millions) will be alive after a breast cancer diagnosis and more than half a million patients (2.1% of all men) will be alive after a prostate cancer diagnosis (Table [3](#Tab3){ref-type="table"}). The largest 10-year increases are foreseen for prostate (+ 85%) and for thyroid cancers (+ 79%, 212,863 cases), which will become the third most frequent prevalent cancer types among Italian women. A more than 50% increases are also expected in 2020 for prevalence after diagnosis of testicular cancer (63,395 patients) or skin melanoma (169,900). A limited change in prevalence (variations \< 10%) is expected for ovary, larynx, and stomach, with cervical cancer being the only cancer type showing a decline in prevalence (− 13%) (Table [3](#Tab3){ref-type="table"}).Table 3Projected complete prevalence (cases) at January 1,  2020 by sex and 10-year variations in ItalyPrevalent casesVariation (%)202010-year periodCancer Type^a^MenWomenTotalMenWomenTotalAll types but skin non-melanoma1687,0491,922,0863,609,13541.3%33.1%36.8%Upper aero-digestive tract36,08121,83157,91134.9%41.5%37.3%Stomach50,32732,03382,3609.5%−9.9%1.0%Colon, Rectum, Anus280,277233,245513,52251.1%35.7%43.7%Liver25,234853133,76544.6%16.4%36.2%Larynx47,015600653,0204.9%36.3%7.7%Lung77,15940,657117,81622.4%71.4%35.8%Skin Melanoma80,06989,831169,90078.0%56.2%65.8%Connective Tissue17,04011,81528,85544.9%19.1%33.1%Female Breast834,154834,15437.9%37.9%Cervix Uteri51,13651,136−13.2%−13.2%Corpus Uteri (endometrium)122,553122,55318.6%18.6%Ovary49,80749,8079.2%9.2%Prostate563,960563,96084.9%84.9%Testis63,39563,39567.1%67.1%Kidney97,24947,151144,40054.8%33.8%47.2%Bladder255,01558,608313,62432.4%22.6%30.4%Brain and central nervous system23,50529,31452,81945.9%26.7%34.6%Thyroid45,949166,914212,86380.1%78.8%79.1%Hodgkin Lymphoma37,69229,31467,00635.5%43.5%38.9%Non- Hodgkin Lymphoma82,78073,584156,36445.7%36.5%41.2%Leukaemias45,88039,10084,98027.1%25.3%26.3%Multiple Myeloma19,47217,15936,63152.3%39.8%46.1%^a^ Cancer types with more than 20,000 prevalent cases at 2010Table 4Projected complete prevalence at January 1, 2020 by sex and age groups in Italy ^a^SEX, Cancer typePrevalent casesPrevalence proportion per 100,000All ages%00-4445-7475+All ages00-4445-7475+MEN and WOMEN All types but skin non-melanoma3,609,135100.0%228,1451,897,5431,483,448573172616,38321,657 Colon, rectum, anus513,52214.2%4954231,800276,7678081520803952 Skin melanoma169,9004.7%24,038101,18044,68227176857673 Female breast834,15423.1%29,758498,614305,781262220182157297 Corpus uteri (endometrium)122,5533.4%170765,76555,0813791011041269 Prostate563,96015.6%1174255,514307,272205612563412,343 Bladder313,6248.7%4130128,332181,1625631513232836 Thyroid212,8635.9%41,112145,56226,1893091271084379 Non-Hodgkin lymphoma156,3644.3%14,94887,25554,16124747739789MEN All types but skin non-melanoma1687,049100%95,056834,967757,026544461515,67828,728 Colon, rectum, anus280,27716.6%2250135,206142,8219021325735267 Skin melanoma80,0694.7%876050,43720,87225657898815 Prostate563,96033.4%1174255,514307,272205612563412,343 Bladder255,01515.1%2636106,086146,2949582023235932 Thyroid45,9492.7%914131,444536414259490209 Non-Hodgkin lymphoma82,7804.9%895949,51324,30927158871946WOMEN All types but skin non-melanoma1,922,086100%133,0891,062,575726,422599288817,37417,007 Colon, rectum, anus233,24512.1%270496,594133,9477201716333105 Skin melanoma89,8314.7%15,27850,74223,811284102822581 Breast834,15443.4%29,758498,614305,781262220182157297 Corpus uteri (endometrium)122,5536.4%170765,76555,0813791011041269 Bladder58,6083.0%149422,24634,86819510405859 Thyroid166,9148.7%31,971114,11920,8255082181761516 Non-Hodgkin lymphoma73,5843.8%598937,74329,85222537618688^a^ Most frequent cancer types are shown: Cancer types or combinations with \> 100,000 prevalent cases

Nearly 22% (21,657/100,000) of population aged ≥75 years in 2020 will have had a previous cancer diagnosis (Table [4](#Tab4){ref-type="table"}). Below 45 years of age, prevalent cases will be 228,145 (i.e., 0.8% of all cases, 726/100,000) and, in both sexes, the most frequent cancer type will be thyroid cancer, experienced by 31,971 women and 9141 men.

Prevalent cases diagnosed within 2 years were the only group showing a negligible increase from 2010 to 2020 (+ 3% in the examined period), while a 19% increase was observed for cases diagnosed between 2 and 5 years before, 30-34% for cases diagnosed between 5 and 20 years earlier, and 45% increased for long-term survivors diagnosed ≥20 years before (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Complete cancer prevalence (proportions) in Italy from 2006 to 2020 by years since diagnosis. \*Data for 2006 obtained from ref. 21. Filled symbols (e.g., •) represent estimated values, empty symbols (e.g., ο) represent projected values

Discussion {#Sec8}
==========

In 2010, 2.6 million people were living in Italy after a cancer diagnosis and this number will reach 3.6 million in 2020, increasing from 4.6% to 5.7% (i.e., one out of 17 Italians) of the overall population. The estimated overall trend in the present decade in Italy (+ 3.2% per year) is comparable to that estimated in the same period in the USA (+ 2.8% per year) \[[@CR5]\], UK (+ 3.3%) \[[@CR4]\], and Switzerland (+ 2.5%) \[[@CR6]\].

The expected 37% increase in the present decade in Italy will be more marked (i.e., nearly + 50%) among long-term survivors diagnosed ≥20 years before; they will be more than half a million in Italy (519,356), 14% of all prevalent cases (11% in men and 18% in women). Most of them can be considered as cured since they had already reached a similar life expectancy (i.e., death rates) of the corresponding general population \[[@CR14]\].

A higher proportion of women (55%) than that of men emerged among prevalent cancer cases at 2010 in the present Italian study, in agreement with findings from most studies conducted in other countries \[[@CR4]--[@CR6], [@CR9]\] but France (where 53% were men, 6.4% of the French population) \[[@CR8]\]. In Italy, female breast cancer cases represented 23% of all prevalent cases, and affected the distribution of cancer prevalence by age. The thyroid cancer epidemic in Italy also contributed to an excess in females, below age 45 years thyroid cancer was the most frequent prevalent type in 2010 (29,340 men and women), and this number will substantially increase to more than 41,000 in 2020. It should be noted, however, that a large proportion of thyroid cancer incidence and prevalence may be affected by overdiagnosis; i.e., the detection of cancer cases that would not otherwise result in causing symptoms or deaths \[[@CR23], [@CR24]\].

An important role on variation of cancer prevalence is played by screening programmes, inducing a reduction of cervical and colorectal prevalent cancers cases, while early detection of breast and prostate cancers may inflate number of prevalent cases \[[@CR25]\]. In particular, screening can prevent cervical cancer, with a consequent major effect on prevalence reduction, i.e., − 13% in 10 years in the present study.

Distribution of cancer prevalence by age is also noteworthy. In 2010, 37% of prevalent patients were 75 years or older (38% in men, 35% in women). In this age group, they will reach 41% in 2020, with more than 20% of men and 14% of women will have experienced a previous cancer diagnosis. These proportions were similar to those reported by other studies, showing also that elderly cancer patients had more severe comorbidity conditions than non cancer patients \[[@CR26]\].

At the opposite end of the age spectrum, 8% of Italian prevalent cases were younger than 44 years of age and 10% were aged 45--54 years. It has been recently estimated that 44,135 persons living in Italy in 2010 had had a cancer diagnosis during childhood \[[@CR27]\]; they represented 0.07% of the Italian population and 1.7% of prevalent cases diagnosed at any age. In similar studies conducted in the USA \[[@CR28]\], a substantial proportion of morbidities emerged in childhood cancer patients several years after diagnosis, and there is growing awareness on potentially long-term risks affecting the survivors' future physical, cognitive, and/or psychosocial health \[[@CR29]\]. The impact of a cancer diagnosis is rather different between younger and older survivors, the first facing more pronounced socio-economic consequences \[[@CR30], [@CR31]\], as well as psychosocial impairments in fertility and sexuality \[[@CR32], [@CR33]\].

We acknowledge the several limitations of our analyses. First, data from Italian cancer registries (AIRTUM) included one third of the Italian population in 2010 and the representativeness for the national prevalence estimates may be questionable \[[@CR34]\]. To overcome this issue, we adjusted estimated proportions in cancer registry areas for the age distribution of the whole Italian population. Moreover, since cancer registries have been active in Italy from a relatively recent time period, the complete prevalence has been estimated through statistical models. Notably, the validation of complete prevalence estimation by means of COMPREV method in Italy and elsewhere \[[@CR19]\] is reasonably reassuring. In particular, the validation of COMPREV method shows negligible (i.e., \< 5%) differences, when comparing observed prevalence for cancer registries with ≥30 years of observation and estimated prevalence using complete indexes applied to the same registries and truncated data \[21, page 34\].

On the other hand, the strengths of this population-based study are represented by the size of the study population, which included nearly 1.7 million incident cancer cases, and its long-term follow-up, more than a half of these cases were followed-up for \> 20 years post diagnosis. In addition, data and period used were updated in the present study (see [Appendix 1](#Sec10){ref-type="sec"}), including an additional number of years of observation and follow-up, in comparison with previous studies on the same topic \[[@CR21]\].

The accuracy of future projections of prevalence is necessarily uncertain and lies on statistical models based on assumptions reflecting unknown evolution of incidence, survival, and demographic changes. This may also affect comparisons with trends reported in other countries, obtained using different assumptions and statistical models \[[@CR4], [@CR6], [@CR26]\]. In our medium-term projections, the hypothesis that complete prevalence at 2020 can be predicted by a linear function of calendar year as regressor variable is supported by empirical evidence, at least for all cancer types combined and for most frequent cancer types, consistently showing an approximate linear trend in recent years \[[@CR5], [@CR21]\]. Notably, the use of a longer period (5 calendar years) to estimate linear slope did not materially modify the estimates.

Detailed estimates and projections of numbers of persons living after different cancer diagnoses are particularly relevant for policy makers to better plan health care resource allocation and meet cancer patients needs, including not only initial treatment, but also rehabilitation and long-term surveillance. However, to date, guidelines pertaining to survivorship care have been largely based on consensus rather than on empirical evidence \[[@CR35]--[@CR37]\].

In the USA, the main driver of cancer costs growth is population ageing, with an overall increase of 27% by the year 2020 from 2010 levels \[[@CR38]\]. The largest increase in expenditures is attributable to the continuing phase of care (i.e., \> 1-year post-diagnosis and \> 1 year from death) for prostate and female breast cancer, with 42 and 32% increase respectively \[[@CR38]\]. Although health care costs in the continuing phase of care is lower than in the first course of treatment (first year since diagnosis) and in the last year of life, the large number of survivors in the continuing phase of care is driving most of healthcare resources. Similar findings, on the distribution of cancer burden by phase of care, are expected in Italy \[[@CR39]\].

Conclusions {#Sec9}
===========

The availability of reliable and accurate estimates of complete prevalence and predictions of the rising tide of people living after cancer diagnosis may be helpful not only to epidemiologists and health-care planners, but also to clinicians in developing guidelines to enhance and standardize the long-term follow-up of cancer survivors. Furthermore, these estimates are intended for patients to help recovering social activities and supporting rehabilitation demands.

Appendix 1 {#Sec10}
==========

ᅟPopulation and incident cases in Italian cancer registries with ≥7 years of registration in period 1976-2009CANCER REGISTRYPeriod of activityPopulation at January 1st 2010Incident cases up to 2009^a^Period of registrationYears included to 2009(per 1000)Alto Adige - Sudtirol1995--20101549437,119Biella1995--20101518520,362Catania-Messina2003--20117172758,753Catanzaro2003--200972307755Como2003--2011757724,963Ferrara^b^1991--20111935450,925Friuli Venezia Giulia1995--2010151219128,738Genova^b^1986--200924592112,812Latina1996--20111453132,330Mantova1999--20101140427,541Milano1999--2010111215103,283Modena^b^1988--20112267684,155Napoli1996--20111456128,250Nuoro2003--201172197889Palermo2003--20117123940,926Parma^b^1978--20113242080,744Ragusa^b^1981--20112930331,283Reggio Emilia1996--20111450841,379Romagna1993--2011171058119,458Salerno1996--200914108963,293Sassari^b^1992--20111846737,988Siracusa1999--20111140018,927Sondrio1998--20111218113,003Trapani2002--2009842915,591Umbria1994--20111687585,138Varese^b^1976-201134860137,184Veneto^b^1990--2009202097245,898All CRs18,9091,655,687Italy59,190^a^ All types but skin non-melanoma^b^ CRs included to estimate model-based incidence and survival (47% of all cancer cases)

Appendix 2 {#Sec11}
==========

ᅟComplete cancer prevalence (cases and proportion) by cancer type and age at prevalence in Italian men and women at  January 1, 2010Cancer typePrevalent casesPrevalence proportion ×  100,000^a^All ages%00-1415-4445-5455-6465-7475-8485+All ages00-1415-4445-5455-6465-7475-8485+All types but skin non-melanoma2,637,9758747196,699263,746475,879727,578714,197251,12945521028593103663512,06816,62016,700Upper aero-digestive tract42,1781.6%3832165007969211,759941030557601462142209224204Esophagus41920.2%--71354921145311392548--0515283020Stomach81,5073.1%21415447910,65422,23729,49113,2291370649141354669866Small intestine59810.2%--35662712551675160246611--2718293833Colon, rectum, anus357,37913.5%15547217,36253,849105,252123,17752,253611023207746171528213426Liver24,7850.9%119575191047748529767811994313236614218083Biliary tract98160.4%313152415492882337513521600621457590Pancreas12,1280.5%35241093262235753194111621021236617571Larynx49,2171.9%23042469929716,29316,1774676860129129271376321Lung86,7693.3%211415514415,94729,92328,34359761470658216484654394Thymus, heart, mediastinum45010.2%10389884295895963610571391115148Bone13,9320.5%25141683087272119021391411223173234293226Skin melanoma102,4923.9%5217,44817,33920,76722,77417,8206292182180210296388430448Mesothelioma27630.1%--901956051137640965--02820157Kaposi sarcoma76010.3%367271810611605224812941403916275486Connective tissue21,6740.8%4294578309538554349379315763762037547487107Female breast604,84122.9%--26,66382,068128,514165,456142,65859,4832046--23619063516516456435751Vagina and vulva96890.4%172565579822377357019313202132771137183Cervix uteri58,8792.2%44321807310,56913,17715,6417093193038184280397591675Corpus uteri (endometrium)103,3213.9%--1490574521,04731,54831,15812,333342--1313555396411981147Ovary45,6201.7%654058661710,54411,39997293209149134154276352372291Penis42850.2%--914137951309125542214--1922456884Prostate305,04411.6%3438338734,764112,958122,37631,118111205881048413871436878Testis37,9371.4%8617,116849553493317238911871332149197152128133243Kidney98,0653.7%7255211845017,94129,07328,1748491172823101253483674585Bladder240,4339.1%31416411,14435,04970,61487,53531,896416019132485116520412123Choroidal melanoma35140.1%--2644196589299333116--1510162322Brain and central nervous system39,2551.5%106911,6026542649564005401174663134974899911194Thyroid118,8534.5%9929,24127,61727,47421,62210,92918722021127321375357268131Hodgkin lymphoma48,2541.8%26618,8019478833363554085935813811111101019459Non-Hodgkin lymphoma110,7154.2%89113,97915,38022,60827,41723,91665231911061179314458565456Leukemias67,3012.6%338915,065755110,05713,67612,7704793112396486136217291312Multiple myeloma (plasma cell)25,0661.0%--5422044500376627494232043--22469126176149^a^ For sex-specific types proportions were also sex-specific
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